{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:45:59Z","timestamp":1793781959901,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005140","name":"McDermott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005140","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cgh.2025.07.042","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T02:35:07Z","timestamp":1754620507000},"page":"763-771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Agnes H.Y.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Fear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila R.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krugliak Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.07.042_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.042_bib2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials [published correction appears in Lancet. 2022;400:996.]","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.07.042_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn\u2019s disease: a UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.042_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicentre real-world experience of upadacitinib in the treatment of Crohn\u2019s disease","volume":"17","author":"Chugh","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.07.042_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231158235","article-title":"Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis","volume":"16","author":"Ernest-Suarez","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.042_bib8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.07.042_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ueg2.12683","article-title":"Tofacitinib for the treatment of chronic pouchitis: a pilot study","volume":"13","author":"de Jong","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.cgh.2025.07.042_bib10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2022.06.068","article-title":"CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease","volume":"163","author":"Ma","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.07.042_bib11","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.042_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jgh.16386","article-title":"Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain","volume":"39","author":"Allegretti","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.042_bib13","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","volume":"20","author":"D\u2019Haens","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.042_bib14","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2025.07.042_bib15","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2025.07.042_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40262-022-01191-6","article-title":"Upadacitinib population pharmacokinetics and exposure-response relationships in ulcerative colitis patients","volume":"62","author":"Ponce-Bobadilla","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2025.07.042_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S2468-1253(25)00046-9","article-title":"U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis","volume":"10","author":"Noor","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.042_bib18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s13555-023-00961-9","article-title":"Acne among Japanese patients with atopic dermatitis receiving upadacitinib in the phase 3 Rising Up Study","volume":"13","author":"Hayashi","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.cgh.2025.07.042_bib19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","article-title":"Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials","volume":"87","author":"Mendes-Bastos","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2025.07.042_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15,000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"issue":"10S","key":"10.1016\/j.cgh.2025.07.042_bib21","doi-asserted-by":"crossref","first-page":"S1081","DOI":"10.14309\/01.ajg.0001035348.80235.9f","article-title":"S1495 elevation of liver enzymes in patients with inflammatory bowel disease treated with upadacitinib is associated with metabolic risk factors","volume":"119","author":"Klein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.042_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/cancers17050735","article-title":"Cancer risk in IBD patients treated with JAK inhibitors: reassuring evidence from trials and real-world data","volume":"17","author":"Puca","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cgh.2025.07.042_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.cgh.2025.07.042_bib24","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3390\/cancers15082196","article-title":"High VEGFA expression is associated with improved progression-free survival after bevacizumab treatment in recurrent glioblastoma","volume":"15","author":"Alves","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525006688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525006688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T07:18:42Z","timestamp":1779607122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525006688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1542356525006688"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.042","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the AGA Institute","name":"copyright","label":"Copyright"}]}}